AstraZeneca-The MAVRiC Study

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
AstraZeneca AB: The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab
Principal Investigator
Headshot of Danielle Marie Brander
Associate Professor of Medicine
Protocol Number
IRB: PRO00118960
NCT: NCT07024706
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate